display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2)
mNSCLC - L2 - all population
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab alone OAK ... POPLAR
avelumab based treatment
avelumab alone JAVELIN Lung 200 ...
nivolumab based treatment
nivolumab alone CheckMate 078
Tislelizumab RATIONALE 303

Study type:

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons